Teratogenicity of Antiepileptic Medications

 

 Buy Article Permissions and Reprints

ABSTRACT

Antiepileptic drugs (AEDs) are frequently used to treat several conditions that are common in women of childbearing age, including epilepsy, headaches, and mood disorders. Moreover, as in the case of epilepsy and severe psychiatric disease, clinicians frequently do not have the option of stopping these medications or switching to another class of drugs. Overall, AEDs have been associated with an increased risk of major congenital malformations, minor anomalies, specific congenital syndromes, and developmental disorders seen in childhood. However, the differential effects of individual AEDs remain uncertain. Data are accumulating which strongly suggest that these risks are highest in patients receiving polypharmacy and valproate. There is also modest evidence to suggest an increased risk for phenobarbital. While other older AEDs appear to carry some teratogenic risk, there is not adequate evidence to further stratify their risk. Clinical and basic science research regarding newer AEDs suggests equivalent, if not safer, profiles compared with older AEDs, but these data are inconclusive. Management of women with epilepsy should include a discussion of these risks, prophylactic treatment with folic acid, and the minimal use of polypharmacy and valproate needed to maintain optimum seizure control.

REFERENCES

• 1 Mueller-Kueppers M. Embryopathy during pregnancy caused by taking anticonvulsants.  Acta Paedopsychiatr. 1963;  30 401-405
  PubMedGoogle Scholar
• 2 Perucca E. Birth defects after prenatal exposure to antiepileptic drugs.  Lancet Neurol. 2005;  4 781-786
  CrossrefPubMedGoogle Scholar
• 3 Motamedi G K, Meador K J. Antiepileptic drugs and neurodevelopment.  Curr Neurol Neurosci Rep. 2006;  6 341-346
  CrossrefPubMedGoogle Scholar
• 4 Palmieri C, Canger R. Teratogenic potential of the newer antiepileptic drugs: what is known and how should this influence prescribing?.  CNS Drugs. 2002;  16 755-764
  CrossrefPubMedGoogle Scholar
• 5 Rogawski M A, Loscher W. The neurobiology of antiepileptic drugs.  Nat Rev Neurosci. 2004;  5 553-564
  CrossrefPubMedGoogle Scholar
• 6 Hanson J W, Smith D W. The fetal hydantoin syndrome.  J Pediatr. 1975;  87 285-290
  PubMedGoogle Scholar
• 7 Ornoy A. Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy.  Reprod Toxicol. 2006;  22 214-226
  CrossrefPubMedGoogle Scholar
• 8 Freeman M P, Gelenberg A J. Bipolar disorder in women: reproductive events and treatment considerations.  Acta Psychiatr Scand. 2005;  112 88-96
  CrossrefPubMedGoogle Scholar
• 9 Pennell P B. Pregnancy in women who have epilepsy.  Neurol Clin. 2004;  22 799-820
  CrossrefPubMedGoogle Scholar
• 10 Barrett C, Richens A. Epilepsy and pregnancy: report of an Epilepsy Research Foundation Workshop.  Epilepsy Res. 2003;  52 147-187
  CrossrefPubMedGoogle Scholar
• 11 Hallak M, Kupsky W J, Hotra J W et al.. Fetal rat brain damage caused by maternal seizure activity: prevention by magnesium sulfate.  Am J Obstet Gynecol. 1999;  181 828-834
  CrossrefPubMedGoogle Scholar
• 12 Nei M, Daly S, Liporace J. A maternal complex partial seizure in labor can affect fetal heart rate.  Neurology. 1998;  51 904-906
  PubMedGoogle Scholar
• 13 Adab N, Kini U, Vinten J et al.. The longer term outcome of children born to mothers with epilepsy.  J Neurol Neurosurg Psychiatry. 2004;  75 1575-1583
  CrossrefPubMedGoogle Scholar
• 14 Partington M D, McLone D G. Hereditary factors in the etiology of neural tube defects: results of a survey.  Pediatr Neurosurg. 1995;  23 311-316
  PubMedGoogle Scholar
• 15 Duncan S, Mercho S, Lopes-Cendes I et al.. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality.  Epilepsia. 2001;  42 750-753
  CrossrefPubMedGoogle Scholar
• 16 Kallen B. Epidemiology of Human Reproduction. Boca Raton; CRC Press 1988: 133-137
  Google Scholar
• 17 Fried S, Kozer E, Nulman I et al.. Malformation rates in children of women with untreated epilepsy: a meta-analysis.  Drug Saf. 2004;  27 197-202
  CrossrefPubMedGoogle Scholar
• 18 Holmes L B, Harvey E A, Coull B A et al.. The teratogenicity of anticonvulsant drugs.  N Engl J Med. 2001;  344 1132-1138
  CrossrefPubMedGoogle Scholar
• 19 Lindhout D, Omtzigt J G. Pregnancy and the risk of teratogenicity.  Epilepsia. 1992;  33(suppl 4) S41-S48
  PubMedGoogle Scholar
• 20 Strickler S M, Dansky L V, Miller M A et al.. Genetic predisposition to phenytoin-induced birth defects.  Lancet. 1985;  2 746-749
  PubMedGoogle Scholar
• 21 Van der Put N M, Eskes T K, Blom H J. Is the common 677C→T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis.  QJM. 1997;  90 111-115
  PubMedGoogle Scholar
• 22 Dean J C, Moore S J, Osborne A et al.. Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene.  Clin Genet. 1999;  56 216-220
  CrossrefPubMedGoogle Scholar
• 23 Finnell R H, Waes J G, Eudy J D et al.. Molecular basis of environmentally induced birth defects.  Annu Rev Pharmacol Toxicol. 2002;  42 181-208
  CrossrefPubMedGoogle Scholar
• 24 [No authors listed] . Practice parameter: Management issues for women with epilepsy (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 1998;  51 944-948
  PubMedGoogle Scholar
• 25 [No authors listed] . Guidelines for the care of women of childbearing age with epilepsy. Commission on Genetics, Pregnancy, and the Child, International League Against Epilepsy.  Epilepsia. 1993;  34 588-589
  PubMedGoogle Scholar
• 26 Meador K J, Baker G A, Finnell R H et al.. In utero antiepileptic drug exposure: fetal death and malformations.  Neurology. 2006;  67 407-412
  CrossrefPubMedGoogle Scholar
• 27 Pennell P B. The importance of monotherapy in pregnancy.  Neurology. 2003;  60(suppl 4) S31-S38
  CrossrefPubMedGoogle Scholar
• 28 Holmes L B, Wyszynski D F, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience.  Arch Neurol. 2004;  61 673-678
  CrossrefPubMedGoogle Scholar
• 29 Polifka J E, Friedman J M. Medical genetics: 1. Clinical teratology in the age of genomics.  CMAJ. 2002;  167 265-273
  PubMedGoogle Scholar
• 30 Finnell R H, Nau H, Yerby M S. General principles: teratogenicity of antiepileptic drugs. In: Levy RH, Matson BS Antiepileptic Drugs. 4th ed. New York, NY; Raven Press 1995: 209-230
  Google Scholar
• 31 Lindhout D, Omtzigt J G. Teratogenic effects of antiepileptic drugs: implications for the management of epilepsy in women of childbearing age.  Epilepsia. 1994;  35(suppl 4) S19-S28
  CrossrefPubMedGoogle Scholar
• 32 Ardinger H H, Atkin J F, Blackston R D et al.. Verification of the fetal valproate syndrome phenotype.  Am J Med Genet. 1988;  29 171-185
  CrossrefPubMedGoogle Scholar
• 33 Jones K L, Lacro R V, Johnson K A et al.. Pattern of malformations in the children of women treated with carbamazepine during pregnancy.  N Engl J Med. 1989;  320 1661-1666
  PubMedGoogle Scholar
• 34 Jones K L, Johnson K A, Chambers C C. Pregnancy outcome in women treated with phenobarbital monotherapy.  Teratology. 1992;  45 453-454
  PubMedGoogle Scholar
• 35 Wilkie A O, Morris-Kay G M. Genetics of craniofacial development and malformation.  Nat Rev Genet. 2001;  2 458-468
  PubMedGoogle Scholar
• 36 Reinisch J M, Sanders S A, Mortensen E L et al.. In utero exposure to phenobarbital and intelligence deficits in adult men.  JAMA. 1995;  274 1518-1525
  CrossrefPubMedGoogle Scholar
• 37 Dean J C, Hailey H, Moore S J et al.. Long-term health and neurodevelopment in children exposed to antiepileptic drugs before birth.  J Med Genet. 2002;  39 251-259
  CrossrefPubMedGoogle Scholar
• 38 Meador K J, Browning N, Cohen M J et al.. Cognitive outcomes at 2 years old in children of women with epilepsy differ as function of in utero antiepileptic drug.  Neurology. 2007;  68(suppl 1) A337
  PubMedGoogle Scholar
• 39 Schaefer G B, Sheth R D, Bodensteiner J B. Cerebral dysgenesis: an overview.  Neurol Clin. 1994;  12 773-788
  PubMedGoogle Scholar
• 40 Marsh E D, Brooks-Kayal A R, Porter B E. Seizures and antiepileptic drugs: does exposure alter normal brain development?.  Epilepsia. 2006;  47 1999-2010
  CrossrefPubMedGoogle Scholar
• 41 Kaindl A M, Asimiadou S, Manthey D et al.. Antiepileptic drugs and the developing brain.  Cell Mol Life Sci. 2006;  63 399-413
  CrossrefPubMedGoogle Scholar
• 42 Cadigan K M, Nusse R. WNT signaling: a common theme in animal development.  Genes Dev. 1997;  11 3286-3305
  CrossrefPubMedGoogle Scholar
• 43 Wiltse J. Mode of action: inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of beta-catenin-developmental effects of valproic acid.  Crit Rev Toxicol. 2005;  35(8–9) 727-738
  CrossrefPubMedGoogle Scholar
• 44 Dansky L V, Rosenblatt D S, Andermann E. Mechanisms of teratogenesis: folic acid and antiepileptic therapy.  Neurology. 1992;  42(suppl 5) S32-S42
  PubMedGoogle Scholar
• 45 Bittigau P, Sifringer M, Genz K et al.. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain.  Proc Natl Acad Sci U S A. 2002;  99 15089-15094
  CrossrefPubMedGoogle Scholar
• 46 Bjerkedal T, Czeizel A, Goujard J et al.. Valproic acid and spina bifida.  Lancet. 1982;  2 1096
  PubMedGoogle Scholar
• 47 Samren E B, van Duijn C M, Koch S et al.. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy.  Epilepsia. 1997;  38 981-990
  PubMedGoogle Scholar
• 48 Wyszynski D F, Nambisan M, Surve T et al.. Antiepileptic Drug Pregnancy Registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy.  Neurology. 2005;  64 961-965
  CrossrefPubMedGoogle Scholar
• 49 Vajda F J, Eadie M J. Maternal valproate dosage and foetal malformations.  Acta Neurol Scand. 2005;  112 137-143
  CrossrefPubMedGoogle Scholar
• 50 Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide population-based register study.  Acta Paediatr. 2004;  93 174-176
  CrossrefPubMedGoogle Scholar
• 51 Artama M, Auvinen A, Raudaskoski T et al.. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring.  Neurology. 2005;  64 1874-1878
  CrossrefPubMedGoogle Scholar
• 52 Morrow J, Russell A, Guthrie E et al.. Malformation risks of anti-epileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.  J Neurol Neurosurg Psychiatry. 2006;  77 193-198
  CrossrefPubMedGoogle Scholar
• 53 Cunnington M, Tennis P. International Lamotrigine Pregnancy Registry Scientific Advisory Committee . Lamotrigine and the risk of malformations in pregnancy.  Neurology. 2005;  64 955-960
  CrossrefPubMedGoogle Scholar
• 54 Fedrick J. Epilepsy and pregnancy: a report from the Oxford Record Linkage Study.  BMJ. 1973;  2 442-448
  PubMedGoogle Scholar
• 55 Dolovich L R, Addis A, Vaillancourt J M et al.. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies.  BMJ. 1998;  317 839-843
  CrossrefPubMedGoogle Scholar
• 56 Lin A E, Peller A J, Westgate M N et al.. Clonazepam use in pregnancy and the risk of malformations.  Birth Defects Res A Clin Mol Teratol. 2004;  70 534-536
  CrossrefPubMedGoogle Scholar
• 57 Scolnik D, Nulman I, Rovet J et al.. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy.  JAMA. 1994;  271 767-770
  CrossrefPubMedGoogle Scholar
• 58 Loring D W, Meador K J, Thompson W O. Neurodevelopment after in utero exposure to phenytoin and carbamazepine.  JAMA. 1994;  272 850-851
  CrossrefPubMedGoogle Scholar
• 59 Montouris G. Safety of the newer antiepileptic drug oxcarbazepine during pregnancy.  Curr Med Res Opin. 2005;  21 693-701
  CrossrefPubMedGoogle Scholar
• 60 Cunnington M, Ferber S, Quartey G. International Lamotrigine Pregnancy Registry Scientific Advisory Committee . Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study.  Epilepsia. 2007;  48 1207-1210
  CrossrefPubMedGoogle Scholar
• 61 Hunt S, Craig J, Russell A et al.. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register.  Neurology. 2006;  67 1876-1879
  CrossrefPubMedGoogle Scholar
• 62 Ohtahara S, Yamatogi Y. Erratum to “Safety of zonisamide therapy: prospective follow-up survey”.  Seizure. 2007;  16 87-93
  CrossrefPubMedGoogle Scholar
• 63 Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry.  Epilepsy Behav. 2003;  4 310-317
  CrossrefPubMedGoogle Scholar
• 64 Marchi N S, Azoubel R, Tognola W A. Teratogenic effects of lamotrigine on rat fetal brain: a morphometric study.  Arq Neuropsiquiatr. 2001;  59 362-364
  PubMedGoogle Scholar
• 65 Vila Cerén C, Demestre Guasch X, Raspall Torrent F et al.. Topiramate and pregnancy: neonate with bone anomalies.  An Pediatr (Barc). 2005;  63 363-365
  CrossrefPubMedGoogle Scholar
• 66 Finer L B, Henshaw S K. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001.  Perspect Sex Reprod Health. 2006;  38 90-96
  CrossrefPubMedGoogle Scholar
• 67 Schwarz E B, Postlethwaite D A, Yun-yi H et al.. Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women.  Ann Intern Med. 2007;  147 370-376
  PubMedGoogle Scholar
• 68 Pitkin R M. Folate and neural tube defects.  Am J Clin Nutr. 2007;  85 285S-288S
  PubMedGoogle Scholar
• 69 Centers for Disease Control . Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects.  MMWR Recomm Rep. 1992;  41 1-7
  PubMedGoogle Scholar
• 70 Yerby M S. Management issues for women with epilepsy: neural tube defects and folic acid supplementation.  Neurology. 2003;  61(suppl 2) S23-S26
  PubMedGoogle Scholar
• 71 Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy.  Neurology. 2003;  60 575-579
  CrossrefPubMedGoogle Scholar
• 72 Vajda F J, Eadie M J. Maternal valproate dosage and foetal malformations.  Acta Neurol Scand. 2005;  112 137-143
  CrossrefPubMedGoogle Scholar
• 73 Pennell P B. Pregnancy in the woman with epilepsy: maternal and fetal outcomes.  Semin Neurol. 2002;  22 299-308
  Article in Thieme ConnectPubMedGoogle Scholar
• 74 Eberhard-Gran M, Eskild A, Opjordsmoen S. Treating mood disorders during pregnancy: safety considerations.  Drug Saf. 2005;  28 695-706
  CrossrefPubMedGoogle Scholar
• 75 Pennell P B. Antiepileptic drug pharmacokinetics during pregnancy and lactation.  Neurology. 2003;  61(suppl 2) S35-S42
  PubMedGoogle Scholar
• 76 Moslet U, Hansen E S. A review of vitamin K, epilepsy and pregnancy.  Acta Neurol Scand. 1992;  85 39-43
  PubMedGoogle Scholar
• 77 Autret-Leca E, Jonville-Béra A P. Vitamin K in neonates: how to administer, when and to whom.  Paediatr Drugs. 2001;  3 1-8
  PubMedGoogle Scholar

Kimford J MeadorM.D. 

Melvin Greer Professor of Neurology, Department of Neurology, University of Florida

Box 100236, Gainesville, FL 32610

Email: Kimford.meador@neurology.ufl.edu